A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Hospital Israelita Albert Einstein
University of Texas Southwestern Medical Center
Albert Einstein College of Medicine
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
Northwestern University
National Cancer Institute (NCI)
Swiss Cancer Institute
Swiss Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Memorial Sloan Kettering Cancer Center
Guangzhou Medical University
National Cancer Institute (NCI)